Advertisement

Annals of Surgical Oncology

, Volume 26, Issue 2, pp 628–634 | Cite as

Increased SOX9 Expression in Premalignant and Malignant Pancreatic Neoplasms

  • Jennifer L. GnerlichEmail author
  • Xianzhong Ding
  • Cara Joyce
  • Kevin Turner
  • Christopher D. Johnson
  • Haiyan Chen
  • Gerard J. Abood
  • Samuel G. Pappas
  • Gerard V. Aranha
Pancreatic Tumors

Abstract

Background

SOX9, a progenitor cell marker, is important for pancreatic ductal development. Our goal was to examine SOX9 expression differences in intraductal papillary mucinous neoplasms (IPMNs) and ductal adenocarcinoma (PDAC) compared with benign pancreatic duct (BP).

Methods

SOX9 expression was evaluated by immunohistochemistry performed on 93 specimens: 37 BP, 24 low grade (LG) IPMN, 12 high grade (HG) IPMN, and 20 PDAC. A linear mixed-effects model was used to compare the percentage of cells expressing SOX9 by specimen type. A separate linear mixed-effects model evaluated differences in SOX9 expression by staining intensity in pancreatic epithelial cells.

Results

Nuclear SOX9 expression was detected in the epithelial cells of 98% HG IPMN, 93% LG IPMN, 83% PDAC, and 60% BP. Compared with BP, SOX9 was expressed from a significantly greater percentage of cells in LG IMPN, HG IMPN, and PDAC (p < 0.001 for each). BP and PDAC showed greater variability in SOX9 expression in epithelial cells compared with IPMNs which showed strong, homogenous SOX9 expression in almost all cells. Compared with BP, both LG and HG IPMN showed significantly greater SOX9 expression (p < 0.001 for each), but there was no significant difference in SOX9 expression between LG and HG IPMN (p > 0.05). PDAC had significantly higher expression of SOX9 compared with BP but significantly lower SOX9 expression compared with LG or HG IPMN (p < 0.001 for each).

Conclusions

IPMNs demonstrated the highest expression levels of SOX9. SOX9 expression in BP and PDAC demonstrated much more heterogeneity compared with the strong, uniform expression in IPMN.

Notes

Author Contributions

Jennifer Gnerlich: Study concept and design; acquisition, analysis, and data interpretation; drafting of manuscript; critical revision of manuscript; study supervision. Xianzhong Ding: Acquisition, analysis, and data interpretation; drafting of manuscript Cara Joyce: Statistical analysis; acquisition, analysis, and data interpretation; drafting of manuscript; critical revision of manuscript. Kevin Turner: Study concept and design; acquisition, analysis, and data interpretation; drafting of manuscript; critical revision of manuscript. Christopher Johnson: Critical revision of manuscript and drafting of resubmission. Haiyan Chen: Acquisition, analysis, and data interpretation. Gerard Abood: Critical revision of manuscript. Sam Pappas: Study concept and design; critical revision of manuscript. Gerard Aranha: Study concept and design; acquisition, analysis, and data interpretation; critical revision of manuscript; study supervision; administrative and material support.

Disclosure

The authors do not have any disclosures to report.

References

  1. 1.
    Hotz HG, Hotz B, Buhr HJ. Genes associated with epithelial-mesenchymal transition: possible therapeutic targets in ductal pancreatic adenocarcinoma? Anticancer Agents Med Chem. 2011;11(5):448–54.CrossRefPubMedGoogle Scholar
  2. 2.
    Cates JM, Byrd RH, Fohn LE, et al. Epithelial-mesenchymal transition markers in pancreatic ductal adenocarcinoma. Pancreas. 2009;38(1):e1–6.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Lahat G, Lubezky N, Loewenstein S, et al. Epithelial-to-mesenchymal transition (EMT) in intraductal papillary mucinous neoplasm (IPMN) is associated with high tumor grade and adverse outcomes. Ann Surg Oncol. 2014; 21 Suppl 4:S750–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Russell R, Perkhofer L, Liebau S, et al. Loss of ATM accelerates pancreatic cancer formation and epithelial-mesenchymal transition. Nat Commun. 2015;6:7677.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Castellanos JA, Merchant NB, Nagathihalli NS. Emerging targets in pancreatic cancer: epithelial-mesenchymal transition and cancer stem cells. OncoTargets Ther. 2013;6:1261–7.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Su A, He S, Tian B, et al. MicroRNA-221 mediates the effects of PDGF-BB on migration, proliferation, and the epithelial-mesenchymal transition in pancreatic cancer cells. PLoS ONE. 2013;8(8):e71309.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 2006;172(7):973–81.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Savagner P. Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays. 2001;23(10):912–23.CrossRefPubMedGoogle Scholar
  9. 9.
    Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871–90.CrossRefPubMedGoogle Scholar
  10. 10.
    Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Investig. 2009;119(6):1420–8.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Weber CE, Li NY, Wai PY, Kuo PC. Epithelial-mesenchymal transition, TGF-beta, and osteopontin in wound healing and tissue remodeling after injury. J Burn Care Res. 2012;33(3):311–8.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Nakamura M, Tokura Y. Epithelial-mesenchymal transition in the skin. J Dermatol Sci. 2011;61(1):7–13.CrossRefPubMedGoogle Scholar
  13. 13.
    Hudson LG, Newkirk KM, Chandler HL, et al. Cutaneous wound reepithelialization is compromised in mice lacking functional Slug (Snai2). J Dermatol Sci. 2009;56(1):19–26.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Savagner P, Kusewitt DF, Carver EA, et al. Developmental transcription factor slug is required for effective re-epithelialization by adult keratinocytes. J Cell Physiol. 2005;202(3):858–66.CrossRefPubMedGoogle Scholar
  15. 15.
    Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2(6):442–54.CrossRefPubMedGoogle Scholar
  16. 16.
    Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008;14(6):818–29.CrossRefPubMedGoogle Scholar
  17. 17.
    Yamada S, Fuchs BC, Fujii T, et al. Epithelial-to-mesenchymal transition predicts prognosis of pancreatic cancer. Surgery. 2013;154(5):946–54.CrossRefPubMedGoogle Scholar
  18. 18.
    Schonleben F, Qiu W, Bruckman KC, et al. BRAF and KRAS gene mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC) of the pancreas. Cancer Lett. 2007;249(2):242–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Wada K. p16 and p53 gene alterations and accumulations in the malignant evolution of intraductal papillary-mucinous tumors of the pancreas. J Hepatobiliary Pancreat Surg. 2002;9(1):76–85.CrossRefPubMedGoogle Scholar
  20. 20.
    Cheung M, Briscoe J. Neural crest development is regulated by the transcription factor Sox9. Development. 2003;130(23):5681–93.CrossRefPubMedGoogle Scholar
  21. 21.
    Foster JW, Dominguez-Steglich MA, Guioli S, et al. Campomelic dysplasia and autosomal sex reversal caused by mutations in an SRY-related gene. Nature. 1994;372(6506):525–30.CrossRefPubMedGoogle Scholar
  22. 22.
    Gordon CT, Tan TY, Benko S, et al. Long-range regulation at the SOX9 locus in development and disease. J Med Genet. 2009;46(10):649–56.CrossRefPubMedGoogle Scholar
  23. 23.
    Lynn FC, Smith SB, Wilson ME, et al. Sox9 coordinates a transcriptional network in pancreatic progenitor cells. Proc Natl Acad Sci U S A. 2007;104(25):10500–5.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Seymour PA, Freude KK, Tran MN, et al. SOX9 is required for maintenance of the pancreatic progenitor cell pool. Proc Natl Acad Sci U S A. 2007;104(6):1865–70.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Chakravarty G, Moroz K, Makridakis NM, et al. Prognostic significance of cytoplasmic SOX9 in invasive ductal carcinoma and metastatic breast cancer. Exp Biol Med (Maywood). 2011;236(2):145–55.CrossRefPubMedGoogle Scholar
  26. 26.
    Darido C, Buchert M, Pannequin J, et al. Defective claudin-7 regulation by Tcf-4 and Sox-9 disrupts the polarity and increases the tumorigenicity of colorectal cancer cells. Cancer Res. 2008;68(11):4258–68.CrossRefPubMedGoogle Scholar
  27. 27.
    Zalzali H, Naudin C, Bastide P, et al. CEACAM1, a SOX9 direct transcriptional target identified in the colon epithelium. Oncogene. 2008;27(56):7131–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Sashikawa Kimura M, Mutoh H, Sugano K. SOX9 is expressed in normal stomach, intestinal metaplasia, and gastric carcinoma in humans. J Gastroenterol. 2011;46(11):1292–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Jiang SS, Fang WT, Hou YH, et al. Upregulation of SOX9 in lung adenocarcinoma and its involvement in the regulation of cell growth and tumorigenicity. Clin Cancer Res. 2010;16(17):4363–73.CrossRefPubMedGoogle Scholar
  30. 30.
    Wang H, Leav I, Ibaragi S, et al. SOX9 is expressed in human fetal prostate epithelium and enhances prostate cancer invasion. Cancer Res. 2008;68(6):1625–30.CrossRefPubMedGoogle Scholar
  31. 31.
    Kopp JL, von Figura G, Mayes E, et al. Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;22(6):737–50.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Shroff S, Rashid A, Wang H, et al. SOX9: a useful marker for pancreatic ductal lineage of pancreatic neoplasms. Hum Pathol. 2014;45(3):456–63.CrossRefPubMedGoogle Scholar
  33. 33.
    Meng F, Takaori K, Ito T, et al. Expression of SOX9 in intraductal papillary mucinous neoplasms of the pancreas. Pancreas. 2014;43(1):7–14.CrossRefPubMedGoogle Scholar
  34. 34.
    Pan JJ, Yang MH. The role of epithelial-mesenchymal transition in pancreatic cancer. J Gastrointest Oncol. 2011;2(3):151–6.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Furuyama K, Kawaguchi Y, Akiyama H, et al. Continuous cell supply from a Sox9-expressing progenitor zone in adult liver, exocrine pancreas and intestine. Nat Genet. 2011;43(1):34–41.CrossRefPubMedGoogle Scholar
  36. 36.
    Tanaka T, Kuroki T, Adachi T, et al. Evaluation of SOX9 expression in pancreatic ductal adenocarcinoma and intraductal papillary mucinous neoplasm. Pancreas. 2013;42(3):488–93.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  • Jennifer L. Gnerlich
    • 1
    Email author
  • Xianzhong Ding
    • 2
  • Cara Joyce
    • 3
  • Kevin Turner
    • 4
  • Christopher D. Johnson
    • 1
  • Haiyan Chen
    • 2
  • Gerard J. Abood
    • 4
  • Samuel G. Pappas
    • 4
  • Gerard V. Aranha
    • 4
  1. 1.Department of SurgeryLSU Health Sciences CenterNew OrleansUSA
  2. 2.Department of PathologyLoyola University Medical CenterMaywoodUSA
  3. 3.Department of Public Health SciencesLoyola University Medical CenterMaywoodUSA
  4. 4.Department of SurgeryLoyola University Medical CenterMaywoodUSA

Personalised recommendations